Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Myelodysplastic Syndromes 8Leukemia, Myeloid, Acute 8Multiple Myeloma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Hematologic Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myelomonocytic, Chronic 2Graft vs Host Disease 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Anemia, Aplastic 2Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocythemia, Essential 1Soft Tissue Neoplasms 1Sezary Syndrome 1

Interventions

Vincristine 8X-Rays 6Temozolomide 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Cyclophosphamide 6Specimen Handling 5Irinotecan 5Nuclear Medicine Department, Hospital 4Biopsy 4Radiotherapy 3Radiation 3Dactinomycin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2Vinorelbine 2Proton Therapy 2LY3023414 2Ifosfamide 2Filgrastim 2Etoposide 2Doxorubicin 2Dexrazoxane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Sirolimus × 90 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡